Meiheng Sun

机构：Hong Kong Baptist University, Chinese University of Hong Kong · ORCID：0000-0003-2197-0439

发表论文 28 篇 · 总被引 556 次 · h-index 8

代表论文

• Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation (2022 · Nature Communications · 被引 192)
• Classifications of triple-negative breast cancer: insights and current therapeutic approaches (2025 · Cell & Bioscience · 被引 62)
• Drug discovery of sclerostin inhibitors (2022 · Acta Pharmaceutica Sinica B · 被引 62)
• Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic Cancer (2023 · International Journal of Molecular Sciences · 被引 16)
• Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives (2024 · Journal of Orthopaedic Translation · 被引 10)
• Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation (2026 · Bone Research · 被引 5)